28 Aug 2026Open access
Structure‐Based Discovery of Fumiquinazolines as Skp2–Cks1 Protein–Protein Interaction Disruptors: Mechanistic Computational Insights and Experimental ValidationPublisher siteChemMedChem, Cancer-related Molecular Pathways
Active, last published 2026
In computational drug discovery methods
Emadeldin M.
Kamel
Scholar“Research focused on Computational Drug Discovery Methods and adjacent fields.”
Beni Suef University
Egypt
Claim Your ProfileEgypt29
H-index
1.8k
Citations
Emadeldin has not officially claimed their profile. If you are Emadeldin, claim it free.
Claim Your Profile
Pioneer
LOCKED
Pathfinder
LOCKED
Scholar
EARNED
Innovator
LOCKED
Inventor
LOCKED
Catalyst
LOCKED
Expert
UPGRADE
01 · About the work
What I study
madeldin M. Kamel is a researcher working on Computational Drug Discovery Methods. A fuller summary will appear once they update their profile.
02 · Reach
Publication output and reach
Emadeldin's work has been cited 1,828 times across 4 active years. Bars show publications per year; the line shows cumulative citation totals across publications first appearing in each year.
03 · Research focus
Topics
Computational Drug Discovery Methods×12Enzyme function and inhibition×11Pharmacogenetics and Drug Metabolism×10Genomics, phytochemicals, and oxidative stress×10Natural product bioactivities and synthesis×9
04 · Where I am
Affiliations
Affiliation on published researchBeni-Suef University, EgyptDrawn from the institution listed on this researcher’s published work.
Research themes (UN SDGs)
05 · Selected work
Recent publications
43 works28 Aug 2026
Targeting the c-Myb–CBP/p300 KIX protein–protein interaction with quinone-methide triterpenes: In silico mechanistic insights and MST biochemical validationPublisher siteJournal of Molecular Graphics and Modelling, Protein Structure and Dynamics
27 Aug 2026
Structure-based discovery of diphenylpyrazines as disruptors of the Skp2–Cks1 protein–protein interaction: computational insights and biochemical validationPublisher siteJournal of Computer-Aided Molecular Design, Cancer-related Molecular Pathways
22 Aug 2026
Structure-guided delineation of umbelliferyl phosphate-based disruptors of the c-Myb–CBP/p300 KIX protein–protein interactionPublisher siteBiophysical Chemistry, Protein Kinase Regulation and GTPase Signaling
18 Aug 2026
Oxygenated 9H-carbazole-3-carbaldehyde scaffolds as cerebral cavernous malformation-relevant protein–protein interaction disruptors of the HEG1–KRIT1 interfacePublisher siteJournal of Computer-Aided Molecular Design, Vascular Malformations Diagnosis and Treatment
4 Aug 2026
Targeting cerebral cavernous malformation signaling through canthin-6-one-mediated disruption of the HEG1–KRIT1 protein–protein interactionPublisher siteJournal of the Indian Chemical Society, Vascular Malformations Diagnosis and Treatment
1 Aug 2026Open access
Breaking the Myb–KIX Alliance: Structure‐Guided Discovery of Biaryl Hydroxy‐Naphthamides as Disruptors of the c‐Myb–CBP/p300 KIX Protein–Protein InteractionPublisher siteArchiv der Pharmazie, Protein Kinase Regulation and GTPase Signaling
30 Jul 2026
Discovery of 1 H-Pyrrolo[2,3-b]pyridine-3-sulfonamides as disruptors of the oncogenic MTDH-SND1 Protein-Protein interaction through integrated in silico and in vitro screeningPublisher siteChemical Papers, Cancer Mechanisms and Therapy
Expert Academic Profiles go further
Citation trend analytics, exportable publication records, and direct enquiry routing from industry and funders.
Are you Emadeldin?
Claim it to verify your details, connect with industry partners, and explore Fractional Domain Expert opportunities through MARATTO™.
African researchers are full of potential that too often goes unrecognised. Your MARATTO™ profile gives your work the commercial pathway it deserves.
Claim Your Profile
Free to claim · takes a minute to verify it’s you